CAJ | 학술논문

目的：探讨尼妥珠单抗联合放化疗治疗局部晚期宫颈癌的疗效及不良反应。方法收集经组织病理确诊的Ⅲ期宫颈癌初诊患者60例，采用随机数字表法将患者随机分为两组，对照组（n ＝30）采用调强放疗和腔内后装治疗及周期化疗，观察组（n ＝30）除调强放疗和腔内后装治疗及周期化疗外，每周放疗前进行尼妥珠单抗200 mg 治疗，共6～7次。结果全部病例放疗结束3个月后评价疗效。观察组：CR 20例、PR 5例、SD 4例，PD 1例，总有效率（CR ＋PR）为83．4％。对照组：CR 18例、PR 3例、SD 6例，PD 3例，总有效率为70．0％，两组差异有统计学意义（χ2＝8．356，P ＜0．05）。观察组与对照组主要不良反应为轻度的放射性直肠炎（16．7％∶13．3％）、放射性膀胱炎（10．0％∶10．0％）、恶心呕吐（50．0％∶46．7％）和白细胞降低（40．0％∶43．3％），两组差异均无统计学意义（χ2＝3．357，P ＝0．719；χ2＝2．717，P ＝0．925；χ2＝5．882，P ＝0．623；χ2＝4．728，P ＝0．687），无皮疹及过敏反应发生。结论尼妥珠单抗可提高局部晚期宫颈癌对放疗的敏感性，提高有效率，且不增加明显不良反应。
목적：탐토니타주단항연합방화료치료국부만기궁경암적료효급불량반응。방법수집경조직병리학진적Ⅲ기궁경암초진환자60례，채용수궤수자표법장환자수궤분위량조，대조조（n ＝30）채용조강방료화강내후장치료급주기화료，관찰조（n ＝30）제조강방료화강내후장치료급주기화료외，매주방료전진행니타주단항200 mg 치료，공6～7차。결과전부병례방료결속3개월후평개료효。관찰조：CR 20례、PR 5례、SD 4례，PD 1례，총유효솔（CR ＋PR）위83．4％。대조조：CR 18례、PR 3례、SD 6례，PD 3례，총유효솔위70．0％，량조차이유통계학의의（χ2＝8．356，P ＜0．05）。관찰조여대조조주요불량반응위경도적방사성직장염（16．7％∶13．3％）、방사성방광염（10．0％∶10．0％）、악심구토（50．0％∶46．7％）화백세포강저（40．0％∶43．3％），량조차이균무통계학의의（χ2＝3．357，P ＝0．719；χ2＝2．717，P ＝0．925；χ2＝5．882，P ＝0．623；χ2＝4．728，P ＝0．687），무피진급과민반응발생。결론니타주단항가제고국부만기궁경암대방료적민감성，제고유효솔，차불증가명현불량반응。
Objective To explore the efficacy and adverse effects of nimotuzumab combined with chemotherapy and radiotherapy in the treatment of locally advanced cervical cancer.Methods Sixty patients with stage Ⅲ cervical cancer by the histopathologic diagnosis were collected,and they were randomly divided into two groups using the random number table method.The control group (n =30)using intensity-modulated radiotherapy,intracavitary afterloading therapy and periodic chemotherapy,the observation group (n =30)in addition to the intensity-modulated radiotherapy,intracavitary afterloading therapy and periodic chemotherapy, the nimotuzumab (200 mg)was given to the patients before weekly radiotherapy.All patients were received 6 to 7 times of treatment.Results The curative effects of all the patients were evaluated after radiotherapy 3 months.In the observation group,there were 20 cases of CR,5 cases of PR,4 cases of SD,1 case of PD,the total effective rate (CR +PR)was 83.3%.In the control group,there were 1 8 cases of CR,3 cases of PR,6 cases of SD,3 cases of PD,the total effective rate was 70.0%.The difference was statistically significant (χ2 =8.356,P <0.05).The main adverse reactions in the observation group and control group included slight radioactive proctitis (1 6.7% vs 1 3.3%),radioactive cystitis (1 0.0% vs 1 0.0%),nausea and vomiting (50.0% vs 46.7%),reduction of white blood cells (40.0% vs 43.3%),with no significant differences (χ2 =3.357,P =0.71 9;χ2 =2.71 7,P =0.925;χ2 =5.882,P =0.623;χ2 =4.728,P =0.687).There were no skin rashes and allergic reactions.Conclusion Nimotuzumab can enhance the locally stage cervical cancer patients′sensitivity on radiotherapy,which can increase the efficacy and doesn′t increase adverse <br> reaction obviously.